Background: SGLT2 inhibitors and Kidney Disease

Sodium-glucose cotransporter 2 (SGLT2) inhibitors (iSGLT2) have established benefits for patients with kidney disease, particularly those with existing renal insufficiency. However, questions remained about their effectiveness in individuals with lower risk profiles – those with minimal protein in their ⁢urine (low ‍albuminuria) and those​ susceptible ‍to a⁢ decrease in glomerular filtration ‍rate (GFR) upon initiation of⁤ treatment, such ⁤as the elderly or those taking ‌certain‌ medications.

GFR is a measure of kidney function, and a significant drop can indicate​ worsening ⁢kidney health. Albuminuria,‌ the presence of albumin ⁢in the urine, is a marker of kidney damage. Traditionally, the greatest benefit from iSGLT2s⁤ was seen in patients with higher ​levels of albuminuria.

The Meta-Analysis: A ​Deep Dive into the Data

An international research team, led by Professor‍ William Herrington of the University of Oxford, conducted a meta-analysis of data from 23,340 participants across four pivotal randomized, placebo-controlled ‌trials:⁣ Empa-REG‍ Outcome, Emperor-Reduced, Emperor-Preserved, and Empa-Kidney.These trials, while not specifically designed to study⁢ these subpopulations, contained sufficient ‌data to allow for a focused analysis.

The researchers examined the effect of empagliflozin, a specific​ SGLT2 inhibitor, on the ‍risk of acute kidney disease, defined ​as⁢ a sustained 50% or greater increase in creatinine levels.

Improved ‍Kidney Health, Nonetheless of the clinical Situation

According to the results published⁣ in the Lancet‍ Diabetes & Endocrinology,​ empagliflozin is ⁣associated with ​a 20% reduction in the risk of acute kidney